Global oncology company BeOne Medicines inaugurated its expanded research and development innovation center in Beijing's Changping district on Tuesday, marking a significant step in strengthening its global research capabilities.

Located in the Zhongguancun Life Science Park, the new facility expands the center's total floor area to 47,674 square meters, accommodating over 1,300 staff members and enhancing capabilities in immuno-oncology, inflammation, and cutting-edge platforms like targeted protein degradation and antibody-drug conjugates.

"The innovation ecosystem and talent pool of the Zhongguancun Life Science Park in Changping district have greatly supported our R&D efforts," Xiaodong Wang, co-founder and chairman of the Scientific Advisory Board of BeOne, said.

"Zanubrutinib, discovered in our R&D Innovation Center in Changping, is a testament to how science transforms patients' lives."

"Going forward, this center will remain a vital innovation engine powering scientific breakthroughs for patients worldwide," Wang added.

BeOne's global R&D network spans multiple countries and regions, with over 40 products in clinical or commercial stages, including 13 new molecular entities advanced in 2024 alone. The expanded Changping center is set to reinforce its leadership in oncology research.

lijing2009@chinadaily.com.cn